439 related articles for article (PubMed ID: 28643901)
1. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Trenkwalder C; Winkelmann J; Oertel W; Virgin G; Roubert B; Mezzacasa A;
Mov Disord; 2017 Oct; 32(10):1478-1482. PubMed ID: 28643901
[TBL] [Abstract][Full Text] [Related]
2. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.
Schneider J; Krafft A; Manconi M; Hübner A; Baumann C; Werth E; Gyr T; Bassetti C
Sleep Med; 2015 Nov; 16(11):1342-1347. PubMed ID: 26498233
[TBL] [Abstract][Full Text] [Related]
3. Investigating the response to intravenous iron in restless legs syndrome: an observational study.
Hornyak M; Scholz H; Kiemen A; Kassubek J
Sleep Med; 2012 Jun; 13(6):732-5. PubMed ID: 22503006
[TBL] [Abstract][Full Text] [Related]
4. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
5. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2018 Feb; 42():7-12. PubMed ID: 29458749
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder.
DelRosso LM; Reuter-Yuill LM; Cho Y; Ferri R; Mogavero MP; Picchietti DL
Sleep Med; 2022 Dec; 100():488-493. PubMed ID: 36265207
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
Bae H; Cho YW; Kim KT; Allen RP; Earley CJ
Sleep Med; 2021 Aug; 84():179-186. PubMed ID: 34157632
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2016 Sep; 25():16-23. PubMed ID: 27823710
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Allen RP; Adler CH; Du W; Butcher A; Bregman DB; Earley CJ
Sleep Med; 2011 Oct; 12(9):906-13. PubMed ID: 21978726
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies.
Yang X; Yang B; Ming M; Li S; Wang F; Zhu Z; Ji C; Long J; Hu F; Xu Z; Ren H; Liu B
Sleep Med; 2019 Sep; 61():110-117. PubMed ID: 31395522
[TBL] [Abstract][Full Text] [Related]
14. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder.
DelRosso LM; Ferri R; Chen ML; Kapoor V; Allen RP; Mogavero MP; Picchietti DL
Sleep Med; 2021 Nov; 87():114-118. PubMed ID: 34562823
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.
Grote L; Leissner L; Hedner J; Ulfberg J
Mov Disord; 2009 Jul; 24(10):1445-52. PubMed ID: 19489063
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
[TBL] [Abstract][Full Text] [Related]
18. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
[TBL] [Abstract][Full Text] [Related]
19. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome.
Park HR; Choi SJ; Joo EY; Allen RP
Sleep Med; 2020 Nov; 75():81-87. PubMed ID: 32853922
[TBL] [Abstract][Full Text] [Related]
20. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
